- Personalis press release ( NASDAQ: PSNL ): Q3 GAAP EPS of -$0.58 beats by $0.06 .
- Revenue of $14.9M (-33.2% Y/Y) beats by $1.26M .
- Gross margin was 16.7% in the three months ended September 30, 2022
- Operating expenses were $29.7 million in the three months ended September 30, 2022
- Net loss was $26.5 million in the three months ended September 30, 2022, and net loss per share was $0.58 based on a weighted-average basic and diluted share count of 45.9 million
- Cash, cash equivalents, and short-term investments were $192.8 million as of September 30, 2022
- FY Outlook :
- Total company revenue is expected to be in the range of $63.0 million to $64.0 million
- Revenue from biopharma and all other customers, excluding the VA MVP, is expected to be in the range of $55.5 million to $56.5 million
- Net loss is expected to be in the range of $111.0 million to $114.0 million
For further details see:
Personalis GAAP EPS of -$0.58 beats by $0.06, revenue of $14.9M beats by $1.26M